J&J Advances Myeloma Domination Plan With Bispecific Tecvayli Approval

First-In-Class Approval In EU

 
• By Andrew McConaghie
Johnson_and_Johnson
J&J is aiming to dominate myeloma with the addition of Tecvayli, the first bispecific antibody approved in the field.

More from New Products

More from Scrip